Trevena (NASDAQ:TRVN) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Trevena (NASDAQ:TRVN) in a research report report published on Wednesday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reissued a buy rating and set a $9.00 target price on shares of Trevena in a research report on Tuesday, April 2nd.

Trevena Stock Down 3.2 %

Shares of NASDAQ TRVN opened at $0.43 on Wednesday. The stock has a fifty day moving average price of $0.46 and a 200 day moving average price of $0.56. The company has a market cap of $7.80 million, a P/E ratio of -0.14 and a beta of 1.11. Trevena has a 12-month low of $0.30 and a 12-month high of $2.80. The company has a current ratio of 4.66, a quick ratio of 4.66 and a debt-to-equity ratio of 8.35.

Trevena (NASDAQ:TRVN) last posted its earnings results on Monday, April 1st. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter. The firm had revenue of ($0.08) million during the quarter, compared to analyst estimates of $0.09 million. Research analysts anticipate that Trevena will post -1.28 EPS for the current fiscal year.

Institutional Trading of Trevena

An institutional investor recently bought a new position in Trevena stock. Armistice Capital LLC acquired a new position in shares of Trevena, Inc. (NASDAQ:TRVN) during the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 797,714 shares of the biopharmaceutical company’s stock, valued at approximately $576,000. Armistice Capital LLC owned about 4.61% of Trevena as of its most recent SEC filing. 13.56% of the stock is currently owned by hedge funds and other institutional investors.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.